Press Release

Baxter's AMIA with SHARESOURCE Telehealth Platform for Home Dialysis Named a Winner of 15th Annual Chicago Innovation Awards

  • Baxter innovation recognized as a leader out of 643 award entries
  • Baxter’s AMIA with SHARESOURCE only medical device for home dialysis therapy with two-way telehealth platform

Chicago Innovation Awards 2016 Winner badgeDEERFIELD, Ill., Oct. 26, 2016 — Baxter International Inc. (NYSE: BAX), a global innovator in renal care for more than 60 years, was named a winner of the 15th annual Chicago Innovation Awards for its recently launched AMIA automated peritoneal dialysis (APD) system with SHARESOURCE remote patient management platform. This year’s awards were presented at the Harris Theater in Chicago on Oct. 25, recognizing the top innovations out a record-setting 643 submissions by regionally headquartered companies or civic groups.

Baxter’s AMIA APD with SHARESOURCE, a two-way, cloud-based telehealth platform, is the newest innovation designed to advance home peritoneal dialysis (PD) therapy. AMIA with SHARESOURCE is the first and only APD medical device to include patient-centric features that help guide end-stage renal disease (ESRD) patients through their home PD therapy, while allowing their healthcare providers to remotely view and manage their therapy.

“It’s an honor for Baxter’s AMIA with SHARESOURCE system to be recognized as a top innovation in Chicago – a city with a rich and diverse history of bringing unique solutions to market that enrich lives,” says Giuseppe Accogli, corporate vice president and president, Baxter Renal. “AMIA with SHARESOURCE is uniquely designed to help support what was an unmet need for more intuitive technology that helps more patients self-administer PD therapy, which is evident in the quick adoption of the system by U.S. healthcare providers and dialysis patients.”

In the United States, there are almost 500,000 people on dialysis therapy.1 Only about 11 percent of those patients currently perform PD therapy in their home. PD therapy is typically completed by patients in their home, at a time of day that is convenient for them. It works by cleaning the blood of toxins and removing extra fluid through the body’s peritoneal cavity.

AMIA was designed to allow patients to administer their own PD therapy in the home setting with intuitive features, such as voice guidance, a touchscreen control panel and the SHARESOURCE remote patient management platform. AMIA also is up to 40 percent smaller and 30 percent lighter than other cyclers on the market, and features a folding design when the touch screen is not in use.2,3 The compact design means AMIA can be packed in a car or taken onboard an airplane, enabling patients to conduct therapy when traveling for work or leisure.

SHARESOURCE allows healthcare providers to securely view their patients’ recently completed home dialysis-related treatment data that is automatically collected after each PD session. Healthcare providers can then act on this information by remotely adjusting their patients’ home device settings without requiring them to travel to the clinic. The SHARESOURCE system also provides a patient’s healthcare team better visibility to their missed treatments. The healthcare provider can then proactively follow up with their patient to address any potential issues.

AMIA with SHARESOURCE is available in the United States. The SHARESOURCE remote patient management platform is also available outside the United States on Baxter’s HOMECHOICE CLARIA system. Baxter’s SHARESOURCE platform recently reached a milestone of helping healthcare providers manage more than 150,000 PD treatments performed in patients’ homes with either AMIA or HOMECHOICE CLARIA.

Rx Only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator's Manual.

About Baxter International Inc.

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

This release includes forward-looking statements concerning Baxter's AMIA and HOMECHOICE CLARIA APD systems and the SHARESOURCE remote patient management platform, including anticipated benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply issues; patient safety issues; changes in law and regulations; breaches or failures of the company’s information technology systems; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.


Baxter, Amia, HomeChoice Claria and Sharesource are registered trademarks of Baxter International Inc.



1Annual Data Report 2015. 2015. Accessed July 18, 2016. http://www.usrds.org.
2Amia Automated PD System Patient Guide. Baxter Healthcare Corporation. Deerfield, IL.
3HomeChoice and HomeChoice PRO APD Systems Patient At-Home Guide. Baxter Healthcare Corporation. Deerfield, IL.